Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is positioned for substantial growth, with expected sales of WAKIX projected to increase from approximately $160 million in 2020 to over $700 million by 2024, driven by its safety and convenience advantages. The company is also advancing its pipeline with promising drug candidates, including pitolisant-GR, which aims to enhance treatment durability and patient adherence by eliminating the need for dose titration. Additionally, Harmony's strong balance sheet supports ongoing research and development, positioning it as a compelling growth opportunity in the neurology sector amidst the anticipated positive outcomes from multiple registrational trials.

Bears say

Harmony Biosciences Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the underperformance of its pipeline, particularly ZYN002, which failed to meet the primary endpoint in the pivotal Phase 3 RECONNECT trial. The company's outlook is further hampered by the risks of increased competition in the sodium oxybate market, potential slowdowns in new patient additions for its product WAKIX, and uncertainties surrounding the success of ongoing clinical trials for several other drug candidates. Additionally, there is concern regarding the impact of an earlier-than-expected entry of generic competition for pitolisant, which could further limit growth prospects.

HRMY has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Strong Buy based on their latest research and market trends.

According to 7 analysts, HRMY has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.